Autifony Therapeutics recruits first patient into Phase IIa trial for first-in-class drug to treat Age Related Hearing Loss. Study follows acceptance of Autifony’s first IND by the FDA

London – UK – 27th April 2015 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that it has recruited the first subject in a Phase IIa study for treatment of Age Related Hearing Loss. This proof of concept study (called CLARITY-1) will explore the potential of AUT00063, Autifony’s first-in-class Kv3 potassium channel modulator, to improve hearing in the elderly by focusing on the discrimination of speech from background noise, which is an area of significant unmet medical need.

Read more (306 kB)